Buscar
Candel Therapeutics Inc
CADLAñadir a la lista de seguimiento
9.560USD
-0.300-3.04%
Cierre 07-24 16:00（ET）Cotizaciones retrasadas 15 min
524.83MCap. mercado
PérdidaP/E TTM
Más Datos de Candel Therapeutics Inc Compañía
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Información de Candel Therapeutics Inc
Símbolo de cotizaciónCADL
Nombre de la empresaCandel Therapeutics Inc
Fecha de salida a bolsaJul 27, 2021
Director ejecutivoTak (Paul Peter)
Número de empleados38
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 27
Dirección117 Kendrick Street,
CiudadNEEDHAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02494
Teléfono16179165445
Sitio Webhttps://www.candeltx.com/
Símbolo de cotizaciónCADL
Fecha de salida a bolsaJul 27, 2021
Director ejecutivoTak (Paul Peter)
Ejecutivos de Candel Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
546.86K
+20.36%
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
--
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
102.27K
+62.81%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
77.36K
-30.31%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Edward J. Benz, Jr., M.D.
Dr. Edward J. Benz, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Renee M. Gaeta, CPA
Ms. Renee M. Gaeta, CPA
Independent Director
Independent Director
--
--
Dr. Gary J. Nabel, M.D., Ph.D.
Dr. Gary J. Nabel, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
546.86K
+20.36%
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
--
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
102.27K
+62.81%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
77.36K
-30.31%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Candel Therapeutics Inc?
Los cinco principales accionistas de Candel Therapeutics Inc son: Mr. Christopher (Chris) Martell
¿Cuántas instituciones poseen acciones de Candel Therapeutics Inc (CADL)?
A fecha de 2026Q1, 186 instituciones poseen acciones de Candel Therapeutics Inc, con un valor de mercado combinado de aproximadamente 24.37M, lo que representa el 33.26% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -3518032.00.